Outcome of Application of Cryopreserved Amniotic Membrane Grafts in the Treatment of Chronic Nonhealing Wounds of Different Origins in Polymorbid Patients: A Prospective Multicenter Study

Svobodova, Alzbeta; Horvath, Vojtech; Balogh, Lukas; Zemlickova, Martina; Fiala, Radovan; Burkert, Jan; Brabec, Marek; Stadler, Petr; Lindner, Jaroslav; Bednar, Jan; Jirsova, Katerina

doi:10.3390/bioengineering10080900

Cited by 4 publications

(1 citation statement)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to wound healing, our results show that AM treatment has unambiguous analgesic properties, which contribute to improving patient comfort and quality of life (Pesteil et al 2007 ; Odet et al 2022 ; Svobodova et al 2023b ). In cases 1–3, who were healed completely, the pain decreased markedly within the first several weeks of treatment by AM allografts; the persisting pain relief was also observed in two patients whose wounds were resistant to AM treatment.…”

Section: Discussionmentioning

confidence: 77%

Cryopreserved amniotic membrane in chronic nonhealing wounds: a series of case reports

Horvath,

Svobodova,

Cabral

et al. 2023

Cell Tissue Bank

Self Cite

View full text Add to dashboard Cite

A case series of the use of amniotic membrane (AM) for treating chronic nonhealing wounds. It presents five cases of polymorbid patients with a total of nine chronic nonhealing wounds. The patient group consisted of four men and one woman with various comorbidities, aged 45–72 years. The mean initial wound size was 15.8 cm2, and the mean time from the onset of the wound to the first application of AM was 122 weeks. The wounds were caused by chronic venous insufficiency and/or peripheral arterial disease. Wounds were treated in a standardized protocol. AM was applied weekly in the first month and then every two weeks. Photo documentation of the wound and microbiological colonization was carried out at each visit. In three out of five patients, the AM treatment effectively promoted healing up to complete wound closure. In two cases, the wounds stayed unhealed despite numerous AM applications. Pain relief was noted in all patients. The success of the treatment was closely tied to patient factors, such as adherence to the prescribed treatment regimen and individual patient characteristics. In some cases, treatment failure was observed, possibly due to underlying comorbidities, wound parameters, or poor patient compliance. AM treatment has the potential to become a viable treatment option for these nonhealing wounds. However, the effectiveness of the treatment may be influenced by various patient factors and the underlying cause of the wound. Therefore, it is crucial to have an individualized treatment plan that considers these particular factors.

show abstract

Section: Discussionmentioning

confidence: 77%

Cryopreserved amniotic membrane in chronic nonhealing wounds: a series of case reports

Horvath,

Svobodova,

Cabral

et al. 2023

Cell Tissue Bank

Self Cite

View full text Add to dashboard Cite

show abstract

Amniotic Membrane Transplantation: Clinical Applications in Enhancing Wound Healing and Tissue Regeneration

Musa,

Chukwuyem,

Enaholo

et al. 2024

Advances in Experimental Medicine and Biology

View full text Add to dashboard Cite

Use of amniotic membrane in hard-to-heal wounds: a multicentre retrospective study

Ditmars,

Kay,

Broderick

et al. 2024

J Wound Care

View full text Add to dashboard Cite

Objective: Hard-to-heal (chronic) wounds negatively impact patients and are a source of significant strain on the healthcare system and economy. These wounds are often resistant to standard of care (SoC) wound healing approaches due to a diversity of underlying pathologies. Cellular, acellular, and matrix-like products, such as amniotic membranes (AM), are a potential solution to these challenges. A growing body of evidence suggests that AM may be useful for treatment-resistant wounds; however, limited information is available regarding the efficacy of dehydrated amniotic membrane (DHAM) on multi-aetiology, hard-to-heal wounds. Therefore, we analysed the efficacy of DHAM treatment in reducing the size of hard-to-heal diabetic and venous leg ulcers (VLUs) that had failed to improve after SoC-based treatments. Method: In this multicentre retrospective study, we analysed wound size during clinic visits for patients being treated for either diabetic or VLUs. During each visit, the treatment consisted of debridement followed by application of DHAM. Each wound was measured after debridement and prior to DHAM application, and wound volumes over time or number of DHAM applications were compared. Results: A total of 18 wounds in 11 patients were analysed as part of this study. Wounds showed a significant reduction in volume after a single DHAM application, and a 50% reduction in wound size was observed after approximately two DHAM applications. These findings are consistent with reports investigating DHAM treatment of diabetic ulcers that were not necessarily resistant to treatment. Conclusion: To our knowledge, this study is the first to directly compare the efficacy of standalone DHAM application to hard-to-heal diabetic and venous leg ulcers, and our findings indicate that DHAM is an effective intervention for resolving these types of wounds. This suggests that implementing this approach could lead to fewer clinic visits, cost savings and improved patient quality of life. Declaration of interest: This research was supported in part by Merakris Therapeutics, US, and facilitated access to deidentified patient datasets, which may represent a perceived conflict of interest; however, the primary data analysis was performed by FSB who is unaffiliated with Merakris Therapeutics. TCB is a founder, employee of and shareholder in Merakris Therapeutics; WSF is a co-founder of, consultant for, and shareholder in Merakris Therapeutics, and was also supported by the National Institutes of Health National Center for Advancing Translational Sciences Clinical and Translational Science Awards Grant KL2 Scholars Program (KL2TR001441). The research was also supported through endowments to WSF from the University of Texas Medical Branch Mimmie and Hallie Smith Endowed Chair of Transplant Research and the John L Hern University Chair in Transplant Surgery.

show abstract

Outcome of Application of Cryopreserved Amniotic Membrane Grafts in the Treatment of Chronic Nonhealing Wounds of Different Origins in Polymorbid Patients: A Prospective Multicenter Study

Cited by 4 publications

References 50 publications

Cryopreserved amniotic membrane in chronic nonhealing wounds: a series of case reports

Cryopreserved amniotic membrane in chronic nonhealing wounds: a series of case reports

Amniotic Membrane Transplantation: Clinical Applications in Enhancing Wound Healing and Tissue Regeneration

Use of amniotic membrane in hard-to-heal wounds: a multicentre retrospective study

Contact Info

Product

Resources

About